Ucb SA (UCB) NPV (CDI)

Sell:€145.70Buy:€145.80€1.05 (0.72%)

Prices delayed by at least 15 minutes
Sell:€145.70
Buy:€145.80
Change:€1.05 (0.72%)
Deal now
Prices delayed by at least 15 minutes
Sell:€145.70
Buy:€145.80
Change:€1.05 (0.72%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Key people

Jean-Christophe Tellier
Chief Executive Officer, Chairman of the Executive Committee, Executive Director
Sandrine Dufour
Executive Vice President, Chief Financial Officer, Member of the Executive Committee
Jean-Luc Fleurial
Executive Vice President, Chief Human Resources Officer, Member of the Executive Committee
Alistair Henry
Executive Vice President, Chief Scientific Officer, Member of the Executive Committee
Denelle J. Waynick Johnson
Executive Vice President, General Counsel, Member of the Executive Committee
Emmanuel Caeymaex
Executive Vice President, Chief Commercial Officer, Member of the Executive Committee
Fiona Du Monceau
Executive Vice President - Patient Evidence, Member of the Executive Committee
Kirsten Lund-jurgensen
Executive Vice President - Patient Supply, Member of the Executive Committee
Xavier Michel
Group Secretary General
Jonathan Peacock
Non-Executive Independent Chairman of the Board
Charles-Antoine Janssen
Non-Executive Vice Chairman of the Board
Cyril Janssen
Non-Executive Director
Cedric Van Rijckevorsel
Non-Executive Director
Jan Berger
Independent Non-Executive Director
Click to see more

Key facts

  • EPIC
    UCB
  • Location
    Belgium
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    BE0003739530
  • Market cap
    €28.54bn
  • Employees
    9,378
  • Shares in issue
    194.51m
  • Exchange
    Euronext Brussels
  • Index
    BEL 20 Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.